Results 11 to 20 of about 11,407 (210)

Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China [PDF]

Clinical Microbiology and Infection, 2020
The aim was to investigate the activity of ceftazidime/avibactam (CAZ/AVI) against carbapenem-resistant Klebsiella pneumoniae (CRKP) and identify the resistance mechanisms before CAZ/AVI coming to Chinese market.Clinical CRKP isolates were continuously collected from 36 tertiary hospitals in China from 1 March 2017 to 31 July 2017.
P, Zhang, Q, Shi, H, Hu, B, Hong, X, Wu, X, Du, M, Akova, Y, Yu   +7 more
openaire   +4 more sources

Resistance to ceftazidime–avibactam and underlying mechanisms

Journal of Global Antimicrobial Resistance, 2020
Ceftazidime-avibactam (CAZ-AVI) is a novel synthetic β-lactamase inhibitor combination. Although the combination has been available clinically for only a few years, cases of resistance to CAZ-AVI have already been reported.In the present review, we summarize the distribution of CAZ-AVI-resistant strains and the possible resistance mechanisms.There are ...
Yuhang Wang, Jin Wang, Rui Wang, Yun Cai
openaire   +5 more sources

Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam

WIREs Mechanisms of Disease, 2022
AbstractCeftazidime/avibactam (CAZ/AVI), a combination of ceftazidime and a novel β‐lactamase inhibitor (avibactam) that has been approved by the U.S. Food and Drug Administration, the European Union, and the National Regulatory Administration in China. CAZ/AVI is used mainly to treat complicated urinary tract infections and complicated intra‐abdominal
Luying Xiong, Xueting Wang, Yuan Wang, Wei Yu, Yanzi Zhou, Xiaohui Chi, Tingting Xiao, Yonghong Xiao   +7 more
openaire   +4 more sources

Identification of a Novel Ceftazidime-Avibactam-Resistant KPC-2 Variant, KPC-123, in Citrobacter koseri Following Ceftazidime-Avibactam Treatment

Frontiers in Microbiology, 2022
This study reported the identification of a novel ceftazidime-avibactam-resistant KPC-2 variant, KPC-123, in a Citrobacter koseri isolated from a patient in a Chinese hospital following ceftazidime-avibactam treatment of infection caused by OXA-232 ...
Lin Wang, Weiyi Shen, Rong Zhang, Jiachang Cai   +3 more
doaj   +3 more sources

OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs [PDF]

mSphere, 2019
Infections due to carbapenemase-producing Gram-negative pathogens are associated with limited treatment options and consequently lead to increased mortality and morbidity.
Christopher Fröhlich, Vidar Sørum, Ane Molden Thomassen, Pål Jarle Johnsen, Hanna-Kirsti S. Leiros, Ørjan Samuelsen   +5 more
doaj   +4 more sources

A Selective Medium for Screening Ceftazidime/Avibactam Resistance in Carbapenem-Resistant Enterobacterales. [PDF]

Front Microbiol, 2022
Ceftazidime/avibactam (CZA) is an alternative antibiotic used for the treatment of infections caused by carbapenem-resistant Enterobacterales (CRE). However, the CZA-resistant CRE strains have been detected worldwide. Therefore, it is critical to screen CZA-resistant CRE strains in colonized patients or a specific population so as to rapidly implement ...
Zeng W, Liao W, Zhao Y, Wang L, Shu H, Jia H, Chen T, Zhang Y, Zhou T, Wu Q.   +9 more
europepmc   +14 more sources

In vivo emergence of cefiderocol and ceftazidime/avibactam cross-resistance in KPC-producing Klebsiella pneumoniae following ceftazidime/avibactam -based therapies [PDF]

Diagnostic Microbiology and Infectious Disease
We described the emergence of ceftazidime/avibactam and cefiderocol cross-resistance in patients with KPC-producing Klebsiella pneumoniae infections. All strains with ceftazidime/avibactam and cefiderocol cross-resistance showed point mutations on KPC Ω ...
Amadesi S., Amedeo A., Gaibani P., Giannella M., Palombo M., Rinaldi M.   +5 more
core   +3 more sources

Ceftazidime-avibactam in ceftazidime-resistant infections [PDF]

The Lancet Infectious Diseases, 2016
One of the important causes of the development of resistance to β-lactam drugs is their overuse. β-lactamase inhibitors have been combined with many β-lactam drugs to resume their efficacy since the emergence of multidrugresistant organisms. Yahuda Carmeli and colleagues recommended the combination of ceftazidimeavibactam as a potential alternative to ...
Yehuda, Carmeli, Jon, Armstrong, Paul, Newell, Greg, Stone, Angela, Wardman   +4 more
openaire   +5 more sources

Susceptibility of clinical Enterobacterales and Pseudomonas aeruginosa isolates to ceftazidimeavibactam in Russia: multicenter local laboratory databased surveillance [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2021
Objective. To assess the in vitro activity of ceftazidime-avibactam against clinical Enterobacterales and Pseudomonas aeruginosa isolates in various regions of Russia based on results of local susceptibility testing by disk diffusion method. Materials
Edelstein M.V., Skleenova E.Yu., Trushin I.V., Kuzmenkov A.Yu., Martinovich А.А., Shek E.A., Shajdullina E.R., Avramenko A.A., Vinogradova A.G., Ivanchik N.V., Sukhorukova M.V., Romanov A.V., Mikotina A.V., Azyzov I.S., Dekhnich A.V., Kozlov R.S., cazavi   +16 more
doaj   +1 more source

Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies

Microbiology Spectrum, 2022
The evolution of bacterial antibiotic resistance is exhausting the list of currently used antibiotics and endangers those in the pipeline. The combination of antibiotics is a promising strategy that may suppress resistance development and/or achieve ...
Congjuan Xu, Xiaoya Wei, Yongxin Jin, Fang Bai, Zhihui Cheng, Shuiping Chen, Xiaolei Pan, Weihui Wu   +7 more
doaj   +1 more source